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Abstract: A general scheme for the synthesis of C8-arylpurine phosphoramidites has been 
developed. C8-Arylation of C8-bromo-2′-deoxyguanosine is the key step and has been 
achieved through the use of a Suzuki coupling. Since the coupling reaction is conducted 
under aqueous conditions, it is unnecessary to protect and then deprotect the hydroxyl 
groups, thus saving several steps and improving overall yields. Once the C8-arylgroup is 
introduced, the glycosidic bond becomes very sensitive to acid catalyzed cleavage. 
Protection of the amino groups as the corresponding N,N-dimethylformamidine derivative 
improves stability of the derivatives. Synthetic C8-arylpurines were successfully used to 
prepare synthetic oligonucleotides. 
Keywords: C8-arylpurine synthesis; Suzuki coupling; phosphoramidite 
 
Introduction 
C8-arylpurines are DNA adducts known to form during exposure to carcinogenic arylhydrazines 
[1,2] and related compounds [3]. These DNA adducts may be related to arylhydrazine carcinogenesis, 
whose mechanism is unknown, but may be related to either mutagenic or conformational effects of the 
modified purines. Recently, it has been proposed that the mutagenic or carcinogenic nature of the C8-
arylpurine adducts is related to the effect they have on DNA conformation. In particular, C8-arylpurine 
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adducts tend to shift the normally preferred B DNA conformation to the Z form. Therefore, it is of 
interest to prepare oligonucleotides that contain this particular type of DNA adduct.  
In order to prepare C8-arylpurine modified oligonucleotides so that conformational and mutational 
effects can be probed, it is necessary to develop procedures whereby C8-arylpurine modified 
oligonucleotides can be made and this, in turn, requires the synthesis of the corresponding 
phosphoramidites. Unfortunately, the reported procedures used to synthesize C8-aryl-2'-deoxy-
guanosine DNA adducts give poor yields and lack scope and reproducibility [4]. Thus, we report here 
a new procedure for the synthesis of C8-arylpurine phosphoramidites. 
In selecting an appropriate arylation reaction, a number of considerations were made. First, 
unprotected nucleosides have poor solubility in organic solvents and it would be advantageous to use a 
reaction that was amenable to aqueous conditions. Second the reaction needs to be efficient at 
generating a carbon-carbon bond between unsaturated substrates. Third, the reaction must have broad 
scope for the synthesis of a variety of C8-arylpurines so that a wide range of these DNA arylated 
adducts can be studied. A reaction that meets all three of these conditions is the Suzuki coupling 
reaction since C8-halogenated purines are readily prepared [5-8] and water soluble palladium ligands 
for this reaction are now available [9,10]. Finally, the Suzuki coupling reaction is typically very 
efficient at coupling unsaturated substrates, so it is an excellent choice for synthesizing C8-
arylpurines. Finally, many arylboronic acids are commercially available or are easily prepared, 
meaning a wide variety of C8-arylpurines may be synthesized via the Suzuki coupling reaction. 
Results and Discussion 
The synthetic schemes employed for the synthesis of C8-arylpurines phosphoramidites are shown in 
Scheme 1. In either case, the first step utilizes the Suzuki coupling reaction between the C8-
bromopurine 1 or 7 and an aryl boronic acid 2 to give the corresponding C8-arylpurine 3 or 8. This 
cross-coupling reaction was conducted in aqueous methanol containing sodium carbonate and 
palladium acetate, at 80 °C for the C8-arylguanine products or room temperature for the C8-
aryladenine products. TPPTS was used as the catalyst in all cases. The reactions were readily followed 
by TLC and run until the C8-bromopurine starting material had been consumed. The isolation of the 
product typically required only adjusting the pH to approximately 7, as this caused the precipitation of 
the cross-coupling product, which was then isolated by filtration. The product was often sufficiently 
pure following a methanol wash, such that further purification was unnecessary. Yields were typically 
80% or better for the phenyl and tolyl derivatives and 67-80% for the carboxyl and TBS protected 
hydroxymethyl derivatives.  
The subsequent steps for phosphoramidite synthesis are typical. First, the purine amino group was 
protected as the N,N-dimethylformamidine derivative (4 and 9) by simply stirring the cross-coupled 
product in N,N-dimethylformamidine dimethyl acetal and methanol. The reactions were essentially 
quantitative and isolation only required partial removal of solvents, water dilution, and filtration of the 
precipitated product. The N,N-dimethylformamidine group has been used as a protecting group for 
either guanine or adenine based phosphoramidites in place of isobutyl (guanine bases) or benzoyl 
(adenine bases). In the course of this work we found that the glycosidic bond of the C8-arylguanines 
was very labile when the exocyclic amino group was protected with the normal isobutyryl group 




(guanine) or benzoyl group (adenine). Dialkylformamidine protection of exocyclic amino groups 
decreased the lability of the glycosidic bond rendered the respective nucleosides less prone to 
decomposition during phosphoramidite synthesis [11,12].  


















Reagents: i) Pd(OAc)2, TPPTS, Na2CO3, MeOH; ii) N,N-dimethylformadinedimethyl acetal, 
MeOH; iii) 4,4'-dimethoxytrityl chloride, TEA, pyridine; iv) (i-Pr2N)P(Cl)OCH2CH2CN, TEA, 
CH2Cl2. 
 
This increased stability facilitates phosphoramidite synthesis, simplified purification and gave 
higher yields. Still, even with this modification, chromatographic purification on silica gel caused near 
complete decomposition, so chromatography was conducted on basic alumina. Nevertheless, a 
C8-Aryladenine Phosphoramidite Synthetic Scheme
C8-Arylguanine Phosphoramidite Synthetic Scheme
a  R = -H
b  R = -CH3
c  R = -COOH
d  R = -CH2OTBS
e  R = -CH2OCH3
iv
11  R'= DMTr, R" = P(OCH2CH2CN)(N(i-Pr)2)
10  R' = DMTr, R" = H
iii iv
6  R'= DMTr, R" = P(OCH2CH2CN)(N(i-Pr)2)
























































































significant amount of material was lost due to decomposition, especially for the C8-arylguanine 
intermediates. Since the ‘crude’ products were usually sufficiently pure (95% or better by NMR), they 
were routinely used without chromatographic purification and chromatographic purification was only 
used for preparing analytical samples. 
The final two steps for phosphoramidite synthesis are the protection of the 3'- and 5'-sugar hydroxyl 
groups. The 5’-hydroxyl group is protected as the dimethoxytrityl ether (DMTr) by reaction of either 4 
or 9 with DMTr-Cl in pyridine containing triethylamine (TEA). As described above, the C8-
arylguanine derivatives are susceptible to cleavage at the glycosidic bond. In addition, the DMTr-ether 
is likewise very prone to acid cleavage. The DMTr ethers did require purification and this was 
achieved by chromatography on alumina but with loss of product due to some decomposition. 
Chromatography on silica resulted in complete decomposition of the DMTr products. 
Phosphotidylation completed phosphoramidite synthesis and this material was typically used with 
minimal purification. In particular, after removal of the reaction solvent and excess TEA, the TEA 
hydrogen chloride salts were removed by dissolving the reaction mixture in a mixture of benzene and 
tetrahydrofuran (THF) and then filtration to remove the TEA salts. Any residual moisture was 
removed by several co-evaporations with benzene and then drying in vacuo over phosphorus 
pentoxide. The resulting phosphoramidites were stable at room temperature or below, as long as 
moisture was excluded. Chromatographic purification was possible and used to obtain analytical 
samples but at the cost of substantial loss of the products 6 or 11. 
These phosphoramidites have been successfully used to make C8-arylpurine modified 
oligonucleotides, including 5'CGCGCG*CGCG3', 5'TGTGTG*TGTG3', and 5'CACACA*CACA3'  
(G* = 8-phenylguanine, 8-tolylguanine, 8-carboxyphenylguanine, 8-hydroxymethylphenylguanine, 
and C8-methoxymethylphenylguanine; A* = 8-phenyladenine, 8-tolyladenine). However, the guanine 
based phosphoramidites formed gels shortly after dissolving in acetonitrile and were manually coupled 
as they could be immediately used. Interestingly, the free carboxylic acid group of 6c did not interfere 
with the oligonucleotide synthesis and no effort was made to protect this group for phosphoramidite 
synthesis. However, the hydroxyl group in hydroxymethylphenyl derivative 12 did require protection 
(i.e., compound 6d) as it otherwise reacts with DMTr-Cl (to give the bis-protected DMTr ether, 
Scheme 2). In turn, the ether was likely cleaved when treated with TCA during oligonucleotide 
synthesis, providing two potential sites for coupling. To ensure this did not occur, the hydroxyl 
methylphenylboronic acid was protected as the TBS ether. This protecting group was stable to all of 
the reaction conditions used for phosphoramidite synthesis and was deprotected, following 
oligonucleotide synthesis by treatment with concentrated ammonium hydroxide, which also removed 












2'-Deoxyguanosine was purchased from USB (Cleveland, OH, USA), tris(3-sulfonatophenyl)-
phosphine hydrate sodium salt (TPPTS) was purchased from Strem Chemicals (Newburyport, MA, 
USA), and all other reagents were purchased from Aldrich Chemical Co (Milwaukee, WI, USA) and 
used as received. Solvents were purchased from Fisher Scientific (Pittsburgh, PA, USA) and were 
purified and dried using standard techniques. IR spectra were obtained on a Perkin-Elmer infrared 
spectrophotometer model 782 in potassium bromide matrix. UV spectra were obtained on a Beckman 
DU640 spectrophotometer. NMR spectra were obtained on a Varian Inova 600 MHz spectrometer, 
referenced to TMS. Proton resonances were assigned based on COSY correlations, carbons bonded to 
protons were assigned by Hetcor correlation, and carbons without protons were assigned on the basis 
of chemical shift. In the case of multiple isomers the reported chemical shifts refer to the major isomer. 
Mass spectra (MS) were recorded on a Finnigan LCQ Deca using electrospray ionization.  
 
General Procedure for the Suzuki Coupling Reaction  
 
Pd(OAc)2 (11 mg, 0.05 mmol), tris(3-sulfonatophenyl)phosphine trisodium (TPPTS; 76 mg,  
0.13 mmol), Na2CO3 (400 mg, 3.77 mmol), compound 1 (0.657 g, 1.90 mmol) and aqueous acetonitrile 
(20 mL, 33%, pre-sparged with nitrogen) were heated at 80 °C under nitrogen. The arylboronic acid 
(2, 2.35 mmol) was then added and the reaction heated at 80 °C, with stirring, for 2.5 hours (ratio 
Pd(OAc)2:TPPTS:Na2CO3:1:2 = 1:2.6:75:38:47). The reaction mixture was cooled to room 
temperature, water (40 mL) added, the pH adjusted to 7 with 10% KH2PO4 or HCl, cooled in an ice 
bath, and filtered. The filtercake was dried in vacuo to yield the arylated product. 
 
C8-Phenyl-2'-deoxyguanosine (3a): Yield 83%; IR (KBr) cm-1 3600-3000, 2930, 1740-1555, 1360, 
1100; 1H-NMR (DMSO-d6) δ ppm 10.80 (1H, bs, NH), 7.65 (2H, dd, J = 1.8, 7.3 Hz, ArH-3,5), 7.52 
(3H, m, ArH-2,4,6), 6.42 (2H, bs, NH2), 6.07 (1H, dd, J = 6.6, 7.8 Hz, H-1'), 5.14 (1H, d, J = 2.4 Hz, 
3'-OH), 4.99 (1H, bs, 5'-OH), 4.33 (1H, m, H-3'), 3.79 (1H, m, H-4'), 3.65 (1H, m, H-5"), 3.54 (1H, m, 
H-5'), 3.17 (1H, p, J = 6.9 Hz, H-2"), 2.02 (1H, ddd, J = 2.4, 6.6, 13.2 Hz, H-2'); 13C-NMR (DMSO-d6) 
Scheme 2. Formation of the bis-DMTr ether of C8-(4-hydroxymethyl)phenyl-2′-




























δ ppm 156.8, 153.1, 152.0, 147.1, 130.3, 129.4, 129.1, 128.6, 117.2, 87.9, 84.7, 71.2, 62.1, 36.6. UV 
(MeCN) max (log ) 279 (4.4); MS m/z 344 (MH+), MS/MS 344 228 (C11H10N5O+).  
 
C8-p-Tolyl-2’-deoxyguanosine (3b): Yield 99%; IR (KBr) cm-1 3600-3260, 3225, 2910, 1690, 1620, 
1350, 1080, 1015; 1H-NMR (DMSO-d6)  ppm 10.73 (1H, s, NH), 7.53 (2H, d, J = 8.40, ArH-3,5), 
7.34 (2H, d, J = 7.80, ArH-2,6), 6.37 (2H, bs, NH2), 6.05 (1H, dd, J = 6.6, 7.8 Hz, H-1'), 5.13 (1H, d,  
J = 4.20, 3'-OH), 4.98 (1H, t, J = 6.00, 5'-OH), 4.33 (1H, h, J = 3.1 Hz, H-3'), 3.78 (1H, m, H-4'), 3.65 
(1, p, J = 5.4 Hz, H-5"), 3.54 (1H, J = 5.4 Hz, H-5'), 3.16 (1H, p, J = 6.9 Hz, H-2"), 2.38 (3H, s, Ar-
CH3), 2.00 (1H, ddd, J = 2.4, 6.6, 9 Hz, H-2'); 
13C-NMR (DMSO-d6)  ppm 156.6, 152.9, 151.9, 147.2, 
139.1, 129.2, 129.0, 127.5, 117.1, 87.9, 84.6, 71.2, 62.1, 36.5, 20.9; UV (MeCN) max (log ) 282 
(4.5); MS: m/z 358 (MH+), MS/MS 358242 (C12H12N5O+).  
 
C8-(4-Carboxyphenyl)-2′-deoxyguanosine (3c): Yield 83%; 1H-NMR (DMSO-d6): δ ppm 10.82 (1H, s, 
NH), 8.07 (2H, d, J = 7.8 Hz, phenyl), 7.80 (2H, d, J = 8.4 Hz, phenyl), 6.48 (2H, s, NH2), 6.10 (1H, t, 
J = 7.2 Hz, H-1′), 5.14 (1H, brs, 3′-OH), 4.96 (1H, brs, 5′-OH), 4.34 (1H, m, H-3′), 3.80 (1H, m, H-4′), 
3.66 and 3.55 (2H, m, H-5′/5′′), 3.11 (1H, m, H-2′′) and 2.05 (1H, ddd, J = 3.0, 6.6, 13.2 Hz, H-2’); 
13C-NMR (DMSO-d6): δ ppm 166.9, 156.6, 153.2, 152.3, 146.1, 134.3, 131.4, 129.5, 129.2, 117.4, 
87.9, 84.5, 71.0, 61.9, and 36.7. UV: ε227 = 13,745 cm-1M-1 and ε285 = 18,054 cm-1M-1. MS: m/z for 
MW 387.35, calculated MH+ 388.35, found 388, 410 (M+Na)+, 426 (M+K)+, 775 (2M+H)+,and 797 
(2M+Na)+. 
 
C8-(4-(TBS-O-methyl)phenyl)-2′-deoxyguanosine (3d): Yield 72%; The TBS protected boronic acid 
was prepared as described by Zheng, et al. [13]; 1H-NMR (DMSO-d6): δ ppm 10.78 (1H, s, NH), 7.62 
(2H, d, J = 8.4 Hz, phenyl), 7.46 (2H, d, J = 8.4 Hz, phenyl), 6.39 (2H, s, NH2), 6.06 (1H, t, J = 7.5 
Hz, H-1′), 5.12 (1H, d, J = 3.6 Hz, 3′-OH), 4.96 (1H, d, J =4.2 Hz, 5′-OH), 4.80 (2H, s, CH2), 4.34 
(1H, m, H-3′), 3.79 (1H, m, H-4′), 3.65 and 3.55 (2H, m, H-5′/5′′), 3.16 (1H, m, H-2′′), 2.02 (1H, m, H-
2′), 0.93 (9H, s, t-butyl), and 0.11 (6H, s, dimethylsilyl); 13C-NMR (DMSO-d6): δ ppm 156.7, 153.0, 
151.9, 147.0, 142.5, 129.0, 128.9, 126.0, 117.1, 87.9, 84.7, 71.2, 63.9, 62.1, 36.6, 25.8, 18.0, and -5.3. 
UV: ε281 = 15,285 cm-1M-1. MS: m/z for MW 487.63, calculated MH+ 488.63, found 488, 510 
(M+Na)+, 526 (M+K)+, 975 (2M+H)+, and 997 (2M+Na)+. 
 
C8-(4-Methoxymethylphenyl)-2′-deoxyguanosine (3e): Yield 67%; 1H-NMR (DMSO-d6): δ ppm 10.76 
(1H, s, NH), 7.63 (2H, d, J = 8.4 Hz, phenyl), 7.47 (2H, d, J = 7.8 Hz, phenyl), 6.39 (2H, s, NH2), 6.07 
(1H, dt, J = 1.8, 7.5 Hz, H-1′), 5.12 (1H, d, J = 4.2 Hz, 3′-OH), 4.97 (1H, t, J = 5.7 Hz, 5′-OH), 4.49 
(2H, s, CH2), 4.33 (1H, m, H-3′), 3.79 (1H, m, H-4′), 3.65 and 3.54 (2H, m, H-5′/5′′), 3.34 (3H, s, 
OCH3), 3.15 (1H, m, H-2′′) and 2.02 (1H, m, H-2′); 
13C-NMR (DMSO-d6): δ ppm 156.6, 153.0, 152.0, 
146.9, 139.7, 129.4, 129.1, 127.5, 117.1, 87.8, 84.6, 73.1, 71.2, 62.1, 57.7, and 36.6. UV: ε221 = 9,377 
cm-1M-1 and ε282 = 15,552 cm-1M-1. MS: m/z for MW 387.40, calculated MH+ 388.40, found 411 
(M+Na)+ and 798 (2M+Na)+. 
 
C8-Phenyl-2'-deoxyadenosine (8a): Yield 85%; IR (KBr) cm-1 3500-3000, 2935, 1700-1550, 1480, 
1450, 1340, 1300, 1250, 1135, 1100, 1060; 1H-NMR (DMSO-d6)  ppm 8.15 (1H, s, H-2), 7.72 (2H, 




m, ArH-3,5), 7.60 (3H, m, ArH-2,4,6), 7.44 (2H, bs, NH2), 6.16 (1H, dd, J =6.6, 8.4 Hz, H-1'), 5.55 
(1H, bs, 5'-OH), 5.23 (1H, bs, 3'-OH), 4.46 (1H, d, J = 4.8Hz, H-3'), 3.88 (1H, h, J =2.2 Hz, H-4'), 3.70 
(1H, dd, J =4.2, 12, H-5"), 3.54 (1H, bd, J =12, H-5'), 3.31 (1H, m, H-2"), 2.15 (1H, ddd, J =1.8, 6.6, 
13.2 H-2'); 13C NMR (DMSO-d6)  ppm 156.1, 152.0, 150.4, 149.9, 130.1, 129.7, 129.5, 128.8, 119.2, 
88.4, 85.7, 71.5, 62.3, 37.2; UV (MeCN) max (log e) 276 (4.12); MS: m/z 328 (MH+), MS/MS 
328212 (C11H10N5+).  
 
C8-p-Tolyl-2'-deoxyadenosine (8b): Yield 80%; IR (KBr) cm-1 3700-2990, 2940, 1655, 1605, 1480, 
1335, 1305, 1095; 1H NMR (DMSO-d6)  ppm 8.14 (1H, s, H-2), 7.60 (2H, d, J = 8.4 Hz, ArH-3,5), 
7.40 (2H, d, J =8.4 Hz, ArH-2,6), 6.14 (1H, dd, J = 6.0, 8.4 Hz, H-1'), 5.57 (1H, bs, 5'-OH), 5.22 (1H, 
bs, 3'-OH), 4.46 (1H, m, H-3'), 3.87 (1H, h, J = 2.2 Hz, H-4'), 3.70 (1H, dd, J = 2.1, 12 Hz, H-5"), 3.54 
(1H, bm, H-5'), 3.30 (1H, m, H-2"), 2.41 (3H, s Ar-CH3), 2.14 (1H, ddd, J = 1.8, 6, 12.6 Hz, H-2'); 
13C-NMR (DMSO-d6)  ppm 156.1, 151.8, 150.6, 149.9, 139.9, 126.8, 129.3, 129.3, 119.1, 88.4, 85.7, 




General Procedure for Dimethylformamidine Protection  
 
The arylpurine 3 (0.35 g, 1.02 mmol) was co-evaporated with dry pyridine (3 × 2 mL) dissolved in 
MeOH (7 mL) and N,N-dimethylformamidine dimethyl acetal (625 uL, 5.0 mmol) then added (ratio 3 
(mmol):MeOH (mL):acetal (mmol) = 1:7:5). The reaction mixture was stirred at room temperature for 
48 hours and then concentrated in vacuo to give 4. 
 
N2-(N,N-Dimethylformamidine)-C8-phenyl-2'-deoxyguanosine (4a): Yield 92%; IR (KBr) cm-1 3600-
3000, 2930, 1680, 1645, 1430, 1345, 1115; 1H-NMR (DMSO-d6)  ppm 11.43 (1H, bs, NH), 8.51 (1H, 
s, CHN), 7.66 (2H, dd, J=1.0, 7.8 Hz, ArH-3,5), 7.55 (3H, m, ArH-2,4,6), 6.11 (1H, t, J = 6.6 Hz,  
H-1'), 5.21 (1H, d, J = 4.80 Hz, 3'-OH), 4.89 (1H, t, J = 4.8 Hz, 5-'OH), 4.43 (1H, q, J = 4.0 Hz, H-3'), 
3.81 (1H, q, J = 3.0 Hz, H-4'), 3.67 (1H, m, H-5"), 3.57 (1H, m, H-5'), 3.22 (1H, h, J = 7.2 Hz, H-2"), 
3.16 (3H, s, CH3N), 3.05 (3H, s, CH3N), 2.08 (1H, ddd, J = 2.4, 6.6, 13.2 Hz, H-2'); 
13C-NMR 
(DMSO-d6)  ppm 158.1, 157.5, 156.8, 152.1, 150.3, 130.2, 129.5, 129.1, 128.7, 120.2, 87.7, 84.8, 
71.0, 62.0, 40.8, 37.0, 34.6; UV (MeCN) max (log ) 317 (4.49) MS m/z 399 (MH+), MS/MS 
399283 (C14H15N6O+).  
 
N2-(N,N-Dimethylformamide)-C8-p-tolyl-2'-deoxyguanosine (4b): Yield 89%; IR (KBr) cm-1 3600-
2700, 1675, 1630, 1570-1500, 1430, 1350, 1290; 1H-NMR (DMSO-d6)  ppm 11.42 (1H, s, NH), 8.50 
(1H, s, HCN), 7.54 (2H, d, J = 7.2 Hz, ArH-3,5), 7.36 (2H, d, J = 7.2 Hz, ArH-2,6), 6.09 (1H, m, H-
1'), 5.23 (1H, m, 3'-OH), 4.91 (1H, m, 5'-OH), 4.43 (1H, m, H-3'), 3.81 (1H, m, H-4'), 3.66 (1H, m, H-
5"), 3.57 (1H, m, H-5'), 3.22 (1H, m, H-2"), 3.15 (3H, s, CH3N), 3.05 (3H, s, CH3N), 2.39 (3H, s, Ar-
CH3), 2.06 (1H, m, H-2'); 
13C-NMR (DMSO-d6)  ppm 158.1,157.6, 156.8, 150.6, 148.2, 139.2, 129.2, 
129.0, 127.3, 120.1, 87.7, 84.9, 71.0, 62.0, 40.8, 37.0, 34.6, 20.9; UV (MeCN) max (log ) 316 (4.29). 
MS: m/z 413 (MH+), MS/MS 413297 (C15H17N6O+).  
 




N2-(N,N-Dimethylformamidine)-C8-(4-carboxyphenyl)-2′-deoxyguanosine (4c): Yield 96%; 1H-NMR 
(DMSO-d6): δ ppm 8.53 (1H, s, HC=N), 8.02 (2H, d, J = 8.4 Hz, phenyl), 7.64 (2H, d, J = 8.4 Hz, 
phenyl), 6.14 (1H, t, J = 7.2 Hz, H-1′), 4.45 (1H, m, H-3′), 3.82 (1H, m, H-4′), 3.68 and 3.58 (2H, m, 
H-5′/5′′), 3.18 (1H, m, H-2′′), 3.16 and 3.05 (3H each, s, N(CH3)2), and 2.10 (1H, ddd, J = 3.0, 6.6, 
13.2 Hz, H-2′); 13C-NMR (DMSO-d6): δ ppm 169.2, 158.1, 156.8, 150.8, 148.0, 138.7, 131.2, 129.1, 
128.5, 120.2, 87.7, 84.7, 71.0, 61.9, 40.8, 37.1, 34.6, and 34.1. UV: ε231 = 17,153 cm-1M-1 and ε318 = 
20,164 cm-1M-1; MS: m/z for MW 442.43, calculated MH+ 443.43, found 443, 465 (M+Na)+, 488 
(M+2Na)+, 885 (2M+H)+, and 907 (2M+Na)+. 
 
N2-(N,N-Dimethylformamidine)-C8-(4-(TBS-O-methyl)phenyl)-2′-deoxyguanosine (4d): Yield 77%; 
1H-NMR (DMSO-d6): δ ppm 11.42 (1H, s, NH), 8.51 (1H, s, HC=N), 7.63 (2H, d, J = 7.8 Hz, phenyl), 
7.48 (2H, d, J = 7.8 Hz, phenyl), 6.11 (1H, t, J = 7.2 Hz, H-1′), 5.20 (1H, d, J = 2.4 Hz, 3′-OH), 4.88 
(1H, m, 5′-OH), 4.81 (2H, s, CH2), 4.44 (1H, m, H-3′), 3.82 (1H, m, H-4′), 3.67 and 3.57 (2H, m, H-
5′/5′′), 3.22 (1H, m, H-2′′), 3.16 and 3.05 (3H each, s, N(CH3)2), 2.08 (1H, m, H-2′), 0.93 (9H, s, t-
butyl), and 0.12 (6H, s, dimethylsilyl); 13C-NMR (DMSO-d6): δ ppm 158.1, 157.5, 156.8, 150.6, 
148.0, 142.7, 129.0, 128.7, 126.0, 120.2, 87.7, 84.8, 71.0, 63.9, 62.0, 40.8, 37.0, 34.6, 25.8, 18.0, and -
5.4. UV: ε229 = 21,603 cm-1M-1 and ε313 = 28,129 cm-1M-1; MS: m/z for MW 542.71, calculated MH+ 
543.71, found 543, 565 (M+Na)+, 1085 (2M)+, and 1107 (2M+Na)+. 
 
N2-(N,N-Dimethylformamidine)-C8-(4-methoxymethylphenyl)-2′-deoxyguanosine (4e): Yield 90%; 1H-
NMR (DMSO-d6): δ ppm 11.45 (1H, s, NH), 8.51 (1H, s, HC=N), 7.64 (2H, d, J = 8.4 Hz, phenyl), 
7.49 (2H, d, J = 7.8 Hz, phenyl), 6.12 (1H, t, J = 7.2 Hz, H-1′), 5.21 (1H, d, J = 4.2 Hz, 3′-OH), 4.88 
(1H, dt, J = 1.8, 6.0 Hz, 5′-OH), 4.50 (2H, s, CH2), 4.44 (1H, m, H-3′), 3.82 (1H, m, H-4′), 3.68 and 
3.57 (2H, m, H-5′/5′′), 3.34 (3H, s, OCH3 ), 3.22 (1H, m, H-2′′), 3.16 and 3.05 (3H each, s, N(CH3)2), 
and 2.08 (1H, m, H-2′); 13C-NMR (DMSO-d6): δ ppm 158.1, 157.5, 156.8, 150.7, 147.9, 139.9, 129.2, 
129.1, 127.6, 120.2, 87.7, 84.8, 73.1, 71.0, 62.0, 57.7, 40.8, 37.0, and 34.6. UV: ε229 = 14,602 cm-1M-1 
and ε314 = 20,834 cm-1M-1; MS: m/z for MW 442.47, calculated MH+ 443.47, found 443, 466 (M+Na)+, 
and 908 (2M+Na)+. 
 
N6-(N,N-Dimethylformamide)-C8-phenyl-2'-deoxyadenosine (9a): Yield 64%; IR (KBr) cm-1 3650-
3000, 2935, 1640, 1570, 1450, 1420, 1340, 1100; 1H-NMR (DMSO-d6)  ppm 8.93 (1H, s, HCN), 8.43 
(1H, s, H-2), 7.76 (2H, m, ArH-3,5), 7.62 (3H, m, ArH-2,4,6), 6.19 (1H, dd, J = 6.6, 8.4, H-1'), 5.34 
(1H, bs, 5'-OH), 5.27 (1H, bs, 3'-OH), 4.48 (1H, m, H-3'), 3.87 (1H, h, J = 2.3 Hz, H-4'), 3.71 (1H, bd, 
J = 11.4 Hz, H-5"), 3.54 (1H, m, H-5'), 3.36 (1H, m, H-2"), 3.20 (3H, s, CH3N), 3.14 (3H, s, CH3N), 
2.17 (1H, ddd, J = 2.4, 6.6, 13.2 Hz, H-2'); 13C-NMR (DMSO-d6)  ppm 159.2, 157.9, 152.2, 152.1, 
151.2, 130.2, 129.7, 129.5, 128.8, 125.7, 88.2, 85.5, 71.3, 62.2, 40.7, 36.9, 34.6; UV (MeCN) max (log 
) 322 (4.38), 256 (4.12); MS: m/z 383 (MH+), MS/MS 383267 (C14H15N6+).  
 
N6-(N,N-Dimethylformamide)-C8-p-tolyl-2'-deoxyadenosine (9b): Yield 97%; IR (KBr) cm-1 3500-
3100, 2920, 1630, 1570, 1460, 1420, 1330, 1110, 1090, 1050; 1H-NMR (DMSO-d6)  ppm 8.92 (1H, 
s, HCN), 8.42 (1H, s, H-2), 7.64 (2H, d, J = 8.40, ArH-3,5), 7.42 (2H, d, J = 8.4, ArH-2,6), 6.18 (1H, t, 
J =7.2 Hz, H-1'), 5.37 (1H, bs, 5'-OH), 5.24 (1H, bs, 3'-OH), 4.48 (1H, m, H-3'), 3.87 (1H, m, H-4'), 




3.71 (1H, bd, J = 12 Hz, H-5"), 3.54 (1H, bd, J = 12 Hz, H-5'), 3.35 (1H, m, H-2"), 3.20 (3H, s, 
CH3N), 3.13 (3H, s, CH3N), 2.42 (3H, s, Ar-CH3), 2.15 (1H, bdd, J = 6, 13.8 Hz, H-2'); 
13C-NMR 
(DMSO-d6)  ppm 159.1, 157.8, 152.3, 152.0, 151.1, 126.8, 140.1, 129.3, 129.4, 125.7, 88.2, 85.5, 
71.4, 62.2, 40.7, 36.9, 34.6, 21.0; UV (MeCN) max (log ) 258 (4.31), 323 (4.56); MS: m/z 397 
(MH+), MS/MS 397281 (C15H17N6+).  
 
General Procedure for Dimethoxytrityl Protection  
 
Compound 4 (0.63 mmol) was dried in vacuo (P2O5), dissolved in pyridine (PYR) (5 mL), TEA 
(0.11 mL) added and then 4,4'-dimethoxytritylchloride (DMTrCl) (0.314 mg, 0.93 mmol) (ratio 4 
(mmol):PYR (mL):TEA (mL):DMTrCl (mmol) = 47:1:6:8.9). The reaction mixture stirred for 2.5 
hours at room temperature, MeOH (3 mL) added to quench the reaction, the solvent was removed in 
vacuo and residual purified (alumina, MeOH:CH2Cl2, 0-10%).  
 
5'-O-(4,4'-Dimethoxytrityl)-N2-(N,N-dimethylformamidine)-C8-phenyl-2'-deoxyguanosine (5a): Yield 
75%; IR (KBr) cm-1 3600-3150, 3065, 2940, 1685, 1630, 1570-1490, 1440, 1340, 1250, 1175, 1110, 
1030. 1H-NMR (acetone-d6)  ppm 8.32 (1H, s, HCN), 7.79 (2H, m, ArH-3,5), 7.51 (3H, m, 3H, ArH-
2,4,6), 7.37 (2H, d, J = 7.8 Hz, ArH-3',5'), 7.249 and 7.238 (4H, d, J = 9.0 Hz, ArH-3",5"), 7.19 (3H, 
m, ArH-2',4',6'), 6.752 and 6.718 (4H, d, J = 9.0 Hz, ArH-2",6"), 6.18 (1H, dd, J = 5.4, 7.8 Hz, H-1'), 
4.68 (1H, dt, J = 5.4, 7.2 Hz, H-3'), 3.98 (1H, m, H-4'), 3.73 (3H, s, CH3O), 3.72 (3H, s, CH3O), 3.40 
(1H, dd, J = 7.2, 9.9 Hz, H-5"), 3.34 (1H, m, H-2"), 3.20 (1H, dd, J = 3.6, 9.9 Hz, H-5'), 3.03 (3H, s, 
CH3N), 2.95 (3H, s, CH3N), 2.17 (1H, m, H-2'); 
13C-NMR (acetone-d6)  ppm 159.6, 159.0, 158.7, 
157.4, 152.1, 150.3, 146.4, 137.3, 137.0, 131.7, 131.1, 130.6, 130.5, 129.7, 129.1, 128.8, 127.8, 121.6, 
114.0, 87.3, 85.8, 72.8, 65.5, 56.0, 55.9, 41.8, 38.4, 35.4; UV (MeCN) max (log ) 320 (4.44); MS: m/z 
701 (MH+), MS/MS 701303 (C21H19O2+), MS/MS 701283 (C14H15N6O+).  
 
5'-O-(4,4'-Dimethoxytrityl)-N2-(N,N-dimethylformamidine)-C8-p-tolyl-2'-deoxyguanosine (5b): Yield: 
27%; IR (KBr) cm-1 2940, 1690, 1635, 1510, 1250, 1175, 1030; 1H-NMR (MeCN-d3)  ppm 8.31 (1H, 
s, HCN), 7.63 (2H, d, J = 8.0 Hz, ArH-3,5), 7.36 (2H, d, J = 7.9 Hz, DMTrH-3',5'), 7.29 (2H, d, J = 8.0 
Hz, ArH-2,6), 7.24 and 7.23 (4H, m, DMTrH-3’,3",5’,5"), 7.18 (2H, m, DMTrH-2,6), 7.16 (1H, m, 
DMTrH-4'), 6.74 and 6.71 (4H, d, J = 6.72 Hz, DMTrH-2’,2",6’,6"), 6.17 (1H, dd, J = 5.4, 8.0 Hz, 
H-1'), 4.68 (1H, q, J = 5.7 Hz, H-3'), 3.98 (1H, ddd, J = 3, 5, 7.5 Hz, H-4'), 3.71 (3H, s, CH3O), 3.70 
(3H, s, CH3O), 3.39 (1H, dd, J = 7.5, 9.9 Hz, H-5"), 3.33 (1H, ddd, J = 5.0, 7.1, 13.3 Hz, H-2''), 3.20 
(1H, dd, J = 3.0, 9.9 Hz, H-5'), 3.00 (3H, s, CH3N), 2.93 (3H, s, CH3N), 2.40 (3H, s, Ar-CH3), 2.17 
(1H, ddd, J =5.7, 8.2, 13.3 Hz, H-2'); 13C-NMR (MeCN-d3)  ppm 159.5, 158.9,158.8, 157.2, 152.0, 
150.4, 146.5, 140.9, 137.2, 137.0, 130.4, 131.0, 130.0, 129.0, 128.7, 128.0, 127.8, 121.2, 114.0, 87.2, 
85.7, 72.8, 65.5, 56.0, 55.9, 41.8, 38.3, 35.3, 21.5; UV (MeCN) max (log ) 322 (4.41), 231 (4.62); 
MS: m/z 715 (MH+), MS/MS 715303 (C21H19O2+), MS/MS 715297 (C15H17N6O+).  
 
5′-O-(DMTr)-N2-(N,N-dimethylformamidine)-C8-(4-carboxyphenyl)-2′-deoxyguanosine (5c): Yield 
31%; 1H-NMR (DMSO-d6): δ ppm 8.32 (1H, s, HC=N), 8.05 (2H, d, J = 7.8, phenyl), 7.83 (2H, d,  
J = 8.4, phenyl), 7.32 (2H, d, J = 8.2 Hz, DMTr-H), 7.17-7.2 (3H, m, DMTrH-3,4,5), 7.19 (2H, d,  




J = 7.8 Hz, DMTrH-3’,5’), 7.18 (2H, d, J = 7.8 Hz, DMTrH-3”,5”), 6.77 (2H, d, J = 7.8 Hz, DMTrH-
2”,6”), 6.73 (2H, d, J = 7.8 Hz, DMTrH-2’,6’), 6.20 (1H, dd, J = 4.8, 7.8, H-1′), 4.57 (1H, q,  
J = 5.9 Hz, H-3′), 3.93 (1H, m, H-4′), 3.71 and 3.70 (3H each, s, OCH3), 3.30 (1H, dd, J = 7.2,10 Hz, 
H-5”), 3.21 (1H, ddd, J = 5.4, 7.2, 13.4 Hz, H-2′′), 3.15 (1H, dd, J = 2.8,10 Hz, H-5′), 3.03 and 2.98 
(3H each, s, N(CH3)2), and 2.20 (1H, ddd, J = 6.0,8.0,13.4 Hz, H-2′); 
13C-NMR (DMSO-d6): δ ppm 
157.9, 157.9, 157.6, 157.5, 156.4, 150.5, 147.5, 144.9, 135.7, 135.6, 129.6, 129.4, 129.3, 129.0, 127.6, 
127.6, 126.5, 120.3, 112.9, 112.9, 85.7, 85.2, 84.1, 70.8, 64.0, 54.9, 54.9, 40.7, 37.4, 34.6, and 34.2; 
UV: (MeCN) max (log ) 233 (4.63) and 322 (4.44); MS: m/z for MW 744.80, calculated MH+ 745.80, 
found 745.767 (M+Na)+, and 1511.0 (2M+Na)+. 
 
5′-O-(DMTr)-N2-(N,N-dimethylformamidine)-C8-(4-(TBS-O-methyl)phenyl)-2′-deoxyguanosine (5d): 
Yield 41%; 1H-NMR (DMSO-d6): δ ppm 11.41 (1H, s, NH), 8.31 (1H, s, HC=N), 7.74 and 7.46 (4H, 
d, J = 8.4, ArH-2,6 and ArH-3,5), 7.33 (2H, d, J = 8.4 Hz, DMTrH-2,6), 7.24 (3H, m, DMTrH-3,4,5), 
7.21 (2H, d, J = 8.5 Hz, DMTrH-3’,5’), 7.18 (2H, d, J = 8.5 Hz, DMTrH-3”,5”), 6.77 (2H, d, J = 8.5 
Hz, DMTrH-2’,6’), 6.73 (2H, d, J = 8.5 Hz, DMTrH-2”,6”), 6.17 (1H, dd, J = 5.4,7.8 Hz, H-1′), 5.28 
(1H, d, J = 5.6 Hz, 3′-OH), 4.81 (2H, s, CH2), 4.57 (1H, p, J = 5.1 Hz, H-3′), 3.93 (1H, m, H-4′), 3.71 
and 3.70 (3H each, s, OCH3), 3.32 (1H, dd, J = 6.3, 10.2 Hz, H-5’or 5′′), 3.21 (1H, p, J = 6.3 Hz, H-
2′′), 3.15 (2H, dd, J = 2.8, 10.2 Hz, H-5′ or 5′′), 3.03 and 2.98 (3H each, s, N(CH3)2), 2.18 (1H, ddd, J 
= 5.8,8,13.7, H-2′), 0.94 (9H, s, t-butyl), and 0.12 (6H, s, dimethylsilyl); 13C-NMR (DMSO-d6): δ ppm 
157.9, 157.9, 157.5, 156.3, 150.4, 148.2, 144.9, 142.6, 135.7, 135.6, 129.6, 129.4, 129.1, 128.9, 127.6, 
127.6, 126.5, 126.0, 120.0, 113.1, 112.9, 112.9, 85.7, 85.2, 84.0, 70.9, 64.0, 63.9, 54.9, 54.9, 40.7, 
37.4, 34.6, 25.8, 18.0, and -5.4; UV: (MeCN) max (log ) 231 (4.60) 316 (4.36); MS: m/z for MW 
845.08, calculated MH+ 846.08, found 845, 867 (M+Na)+, and 1712 (2M+Na)+. 
 
5′-O-(DMTr)-N2-(N,N-dimethylformamidine)-C8-(4-methoxymethylphenyl)-2′-deoxyguanosine (5e): 
Yield 55%; 1H-NMR (DMSO-d6): δ ppm 11.42 (1H, s, NH), 8.31 (1H, s, HC=N), 7.74 (2H, d, J = 8.4 
Hz, ArH-2,6 or 3,5), 7.46 (2H, d, J = 8.4, ArH-2,6 or 3,5), 7.32 (2H, d, J =8.9 Hz, DMTrH-2,6), 7.19 
(2H, d, J = 8.7 Hz, DMTrH-3’,5’), 7.18 (2H, d, J = 8.7 Hz, DMTrH-3”,5”), 7.14-7.18 (3H, m, ArH-3,4 
5), 6.77 (2H, d, J = 8.7 Hz, DMTrH-2”,6”), 6.73 (2H, d, J = 8.7 Hz, DMTrH-2’,6’), 6.17 (1H, dd, J = 
3.0, 6.6 Hz, H-1′), 5.28 (1H, d, J = 4.9 Hz, 3′-OH), 4.57 (1H, p, 5.5 Hz, H-3′), 4.50 (2H, s, CH2), 3.92 
(1H, m, H-4′), 3.71 and 3.70 (3H each, s, OCH3), 3.35 (3H, s, CH3), 3.30 (1H, dd, J = 7,9.9 Hz, H-5′ or 
5′′), 3.20 (1H, ddd, J = 5,6.8,13 Hz, H-2′′), 3.15 (1H, dd, J = 3, 9.9 Hz, H-5′ or 5′′), 3.03 and 2.98 (3H 
each, s, N(CH3)2), and 2.18 (1H, ddd, 5.7, 8, 13.5 Hz, H-2′); 
13C-NMR (DMSO-d6): δ ppm 157.9, 
157.9, 157.5, 156.3, 150.4, 148.1, 144.9, 139.8, 135.7, 135.6, 129.6, 129.4, 129.1, 127.6, 127.6, 127.5, 
126.5, 120.1, 112.9, 112.9, 85.7, 85.2, 84.0, 73.1, 70.9, 64.0, 57.7, 54.9, 54.9, 40.7, 37.4, and 34.6; 
UV: (MeCN) max (log ) 231 (4.54) and 319 (4.37); MS: m/z for MW 744.85, calculated MH+ 745.85, 
found 746, 768 (M+Na)+, 784 (M+K)+, and 1512 (2M+Na)+. 
 
5'-O-(4,4'-Dimethoxytrityl)-N2-(N,N-dimethylformamidine)-C8-phenyl-2'-deoxyadenosine (10a): Yield 
58%; IR (KBr) cm-1 3500-3130, 2940, 2600, 2500, 1670-1530, 1505, 1440, 1420, 1330, 1250, 1170, 
1110, 1040; 1H-NMR (MeCN-d3)  ppm 8.87 (1H, s, HCN), 8.20 (1H, s, H-2), 7.83 (2H, d, J = 7.3 Hz, 
ArH-3,5), 7.55 (3H, m, ArH-2,6), 7.38 (2H, d, J = 7Hz DMTrH-2”,6”), 7.25 and 7.24 (4H, d, J = 8.8 




Hz, DMTrH-3’,3",5’,5"), 7.19 (3H, m, DMTrH-3”,4”,5”), 6.85 and 6.75 (4H, d, J = 8.8 Hz, DMTrH-
2’,2",6’,6"), 6.21 (1H, t, J = 7.0 Hz, H-1'), 4.74 (1H, m, H- 3'), 4.07 (1H, m, H-4'), 3.73 (3H, s, CH3O), 
3.70 (3H, s, CH3O), 3.53 (1H, dd, J = 6.9, 10.3 Hz, H-2"), 3.37 (1H, dd, J = 4.4, 10.3 Hz, H-5"), 3.28 
(1H, dt, J = 7, 13.5 Hz, H-5'), 3.16 (3H, s, CH3N), 3.13 (3H, s, CH3N), 2.17 (1H, ddd, J = 4.2, 7.9, 13.5 
Hz, H-2'). 13C-NMR (MeCN-d3)  ppm 159.6, 159.5, 158.9, 154.2, 153.8, 152.5, 146.4, 137.3, 137.1, 
137.0, 131.1, 130.8, 130.1, 129.7, 129.1, 128.7, 127.7, 124.8, 114.0, 87.4, 86.2, 73.1, 65.4, 56.0, 55.9, 
41.6, 37.4, 35.3; UV(MeCN) max (log ) 320 (4.25); MS: m/z 685 (MH+), MS/MS 685303 
(C21H19O2
+), MS/MS 685267 (C14H15N6+).  
 
5'-O-(4,4'-Dimethoxytrityl)-N2-(N,N-dimethylformamidine)-C8-p-tolyl-2'-deoxyadenosine (10b): Yield 
86%; IR (KBr) cm-1 2940, 1610, 1560, 1250, 1180, 1035; 1H-NMR (MeCN-d3)  ppm 8.86 (1H, s, 
HCN), 8.21 (1H, s, H-2), 7.73 (2H, m, ArH-3,5), 7.38 (2H, m, ArH-3',5'), 7.35 (2H, m, ArH-2,6), 7.25 
(4H, m, ArH-3",5"), 7.22 (2H, m, ArH-2',6'), 7.19 (1H, m, ArH-4'), 6.74 (4H, m, ArH-2",6"), 6.23 (1H, 
m, H-1'), 4.74 (1H, m, H- 3'), 4.05 (1H, m, H-4'), 3.71 (3H, s, CH3O), 3.70 (3H, s, CH3O), 3.52 (1H, 
m, H-5"), 3.34 (1H, m, H-2"), 3.29 (1H, m, H-5'), 3.14 (3H, s, CH3N), 3.13 (3H, s, CH3N), 2.41 (3H, s, 
ArCH3), 2.13 (1H, m, H-2'); 
13C-NMR (MeCN-d3)  ppm 159.7, 158.9, 156.7, 153.0, 152.4, 151.8, 
146.4, 140.6, 137.3, 137.1, 131.1, 130.9, 130.4, 129.1, 128.7, 127.7, 127.2, 124.8, 114.0, 87.4, 86.4, 
73.1, 65.3, 56.0, 55.9, 41.5, 37.4, 35.3, 21.6; UV (MeCN) max (log ) 234 (4.63); MS: m/z 699 (MH+), 
MS/MS 699303 (C21H19O2+), MS/MS 699281 (C15H17N6+).  
 
General Procedure for Phosphoramidite Synthesis  
 
Compound 5 (0.29 mmol) was dried in vacuo (P2O5). CH2Cl2 (3 mL), TEA (80 μL), and  
2-cyanoethyl diisopropylchlorophosphoramidite (CEDClP) (65 μL, 0.29 mmol) were added, the 
reaction at room temperature for 30 min, a second addition of 2-cyanoethyl 
diisopropylchlorophosphoramidite (32 μL, 0.14 mmol) made, and stirring at room temperature 
continued for 30 min (Ratio 5 (mmol):TEA (mmol):CEDClP (mmol):2nd CEDClP (mmol) for all 
reactions = 2:4:2:1). The reaction solvent was removed in vacuo, THF:benzene (1:4, 4 mL) added, the 
mixture stirred for 10 minutes, and then filtered and the filtrate concentrated in vacuo. The residual 
solid was purified by low pressure alumina chromatography (100% EtOAc). 
 
3′-O-[(2-Cyanoethoxy)(diisopropylamino)phosphino]-5′-O-(4,4′-dimethoxytrityl)-N2-(N,N-dimethyl-
formamidine)-C8-phenyl-2′-deoxyguanosine (6a):  Yield 44%; IR (KBr) cm-1 2940, 1675, 1630, 1550-
1500, 1430, 1350, 1250, 1180, 1120; 1H-NMR (acetone-d6)  ppm 8.39 (1H, s, HCN), 7.80 (2H, m, 
ArH-3,5), 7.54 (3H, m, ArH-2,4,6), 7.35 (2H, m, ArH-3',5'), 7.23 (4H, m, ArH-3",5"), 7.19 (2H, m, 
ArH-2',6'), 7.17 (1H, m, ArH-4'), 6.74 (4H, m, ArH-2",6"), 6.21 (1H, m, H-1'), 5.04 (1H, m, H- 3'), 
4.10 (1H, m, H-4'), 4.04 (2H, m, CH2O), 3.75 (3H, s, CH3O), 3.73 (3H, s, CH3O), 3.68 (1H, m, H-2"), 
3.53 (2H, m, CH(CH3)2). 3.36 (1H, m, H-5"), 3.29 (1H, m, H-5'), 3.05 (3H, s, CH3N), 3.01 (3H, s, 
CH3N), 2.72 (2H, m, CH2CN), 2.35 (1H, m, H-2'), 1.13 (12H, m, CH(CH3)2); 
13C-NMR (acetone-d6)  
ppm 159.7, 158.9, 158.6, 157.6, 151.8, 150.2, 146.1, 137.1, 137.0, 136.9, 130.8, 130.7, 130.5, 129.7), 
129.0, 128.9, 127.8, 121.6, 118.4, 114.0, 87.0, 85.0, 76.0, 63.7, 61.0, 56.0, 55.9, 47.1, 41.5, 36.9, 35.5, 
24.9, 21.0; UV (MeCN) max (log ) 323 (4.26), 285 (4.07); MS: m/z 901 (MH+), MS/MS 901683 










formamidine)-C8-p-tolyl-2′-deoxyguanosine (6b): Yield 44%; IR (KBr) cm-1 2970, 1700, 1630, 1540, 
1510, 1345, 1250, 1170, 1115, 1030; 1H-NMR (MeCN-d3)  ppm 8.49 (1H, s, HCN), 7.79 (2H, m, 
ArH-3,5), 7.46 (2H, m, ArH-2,6), 7.50 (2H, m, ArH-3',5'), 7.32 (4H, m, ArH-3",5"), 7.28 (2H, m, ArH-
2',6'), 7.27 (1H, m, ArH-4'), 6.85 (4H, m, ArH-2",6"), 6.31 (1H, m, H-1'), 5.16 (1H, m, H- 3'), 4.21 
(1H, m, H-4'), 3.85 (3H, s, CH3O), 3.84 (3H, s, CH3O), 3.78 (2H, m, CH2O), 3.64 (2H, m, CH(CH3)2). 
3.46 (1H, m, H-5"), 3.44 (1H, m, H-5'), 3.35 (1H, m, H-2"), 3.15 (3H, s, CH3N), 3.11 (3H, s, CH3N), 
2.66 (2H, m, CH2CN), 2.53 (3H, s, ArCH3), 2.44 (1H, m, H-2'), 1.23 (12H, m, CH(CH3)2); 
13C-NMR 
(MeCN-d3)  ppm 159.6, 158.8, 158.1, 157.4, 151.9, 150.9, 146.3, 141.0, 137.2, 137.0, 131.1, 130.4, 
130.3, 129.1, 128.8, 128.0, 127.8, 121.6, 119.4, 114.0, 86.9, 85.4, 77.4, 64.7, 59.5, 56.0, 55.9, 44.2, 
41.9, 38.1, 35.4, 24.9, 21.1; UV (MeCN) max (log ) 322 (4.44), 285 (4.27); MS: m/z 915 (MH+), 
MS/MS 915697 (C41H41N6O5+), MS/MS 915619 (C36H45NO6P+), MS/MS 915303 (C21H19O2+), 
MS/MS 915297 (C15H17N6O+).  
 
3′-O-[(2-Cyanoethoxy)(diisopropylamino)phosphino]-5′-O-(4,4′-dimethoxytrityl)-N6-(N,N-dimethyl-
formamidine)-C8-phenyl-2′-deoxyadenosine (11a): Yield 90%; IR (KBr) cm-1 2970, 1610, 1560, 1510, 
1440, 1415, 1340, 1245, 1175, 1030; 1H-NMR (CDCl3)  ppm 8.94 (1H, s, HCN), 8.31 (1H, s, H-2), 
7.89 (2H, m, ArH-3,5), 7.51 (3H, m, ArH-2,4,6), 7.43 (2H, m, ArH-3',5'), 7.31 (4H, m, ArH-3",5"), 
7.20 (2H, m, ArH-2',6'), 7.17 (1H, m, ArH-4'), 6.75 (4H, m, ArH-2",6"), 6.23 (1H, m, H-1'), 5.06 (1H, 
m, H- 3'), 4.30 (1H, m, H-4'), 3.78 (3H, s, CH3O), 3.76 (3H, s, CH3O), 3.74 (2H, m, CH2O), 3.68 (1H, 
m, H-2"), 3.56 (2H, m, CH(CH3)2), 3.51 (1H, m, H-5"), 3.44 (1H, m, H-5'), 3.26 (3H, s, CH3N), 3.20 
(3H, s, CH3N), 2.54 (2H, m, CH2CN), 2.32 (1H, m, H-2'), 1.18 (12H, m, CH(CH3)2); 
13CNMR (CDCl3) 
 ppm 159.3, 158.4, 158.1, 153.5, 152.8, 151.9, 145.0, 136.4, 136.3, 136.2, 130.3, 130.2, 130.1, 128.7, 
128.4, 127.8, 126.8, 117.5, 117.0, 113.0, 85.6, 85.3, 74.8, 58.5, 55.5, 55.4, 45.6, 43.5, 41.5, 36.2, 35.5, 
24.8, 20.5; UV(MeCN) max (log ) 321 (4.33); MS: m/z 885 (MH+), MS/MS 885667 




formamidine)-C8-p-tolyl-2′-deoxyadenosine (11b): Yield 17%; IR (KBr) cm-1 2975, 1570, 1510, 1420, 
1340, 1250, 1175, 1030; 1H-NMR (MeCN-d3)  ppm 8.87 (1H, s, HCN), 8.25 (1H, s, H-2), 7.74 (2H, 
m, ArH-3,5), 7.38 (2H, m, ArH-3',5'), 7.36 (2H, m, ArH-2,6), 7.24 (4H, m, ArH-3",5"), 7.20 (2H, m, 
ArH-2',6'), 7.18 (1H, m, ArH-4'), 6.75 (4H, m, ArH-2",6"), 6.25 (1H, m, H-1'), 5.12 (1H, m, H- 3'), 
4.17 (1H, m, H-4'), 4.07 (2H, m, CH2O), 3.73 (3H, s, CH3O), 3.71 (3H, s, CH3O), 3.68 (1H, m, H-2"), 
3.55 (2H, m, CH(CH3)2), 3.38 (1H, m, H-5"), 3.31 (1H, m, H-5'), 3.18 (3H, s, CH3N), 3.15 (3H, s, 
CH3N), 2.53 (2H, m, CH2CN, 2.48 (1H, m, H-2'), 2.43 (3H, s, ArCH3), 1.16 (12H, m, CH(CH3)2); 
13C- 
NMR (MeCN-d3)  ppm 159.6, 158.9, 154.2, 153.6, 152.5, 152.2, 146.3, 141.6, 137.4, 137.1, 131.0, 
130.7, 130.4, 129.0, 128.7, 128.5, 127.7, 127.0, 119.5, 113.9, 86.4, 85.9, 74.5, 64.9, 59.7, 56.0, 55.9, 
44.0, 41.5, 37.0, 35.2, 25.0, 21.6, 21.1; UV(MeCN) max (log ) 321 (4.47), 235 (4.53); MS: m/z 889 




(MH+), MS/MS 899681 (C41H41N6O4+), MS/MS 899619 (C36H45NO6P+), MS/MS 899303 
(C21H19O2
+), MS/MS 899281 (C15H17N6+). 
4. Conclusions 
We have developed a general approach to the synthesis of C8-arylpurine phosphoramidites. The 
method is very simple and minimizes the use of protection/deprotection steps. While here we have 
only coupled phenyl and substituted phenyl groups to either 2′-deoxyguanosine or 2′-deoxyadenosine, 
a wide range or aromatic groups with various substituents should work as well. The principle difficulty 
in preparing the C8-arylpurines is that the glycosidic bond is very easily cleaved by acid. Suitable 
selection of the amino protecting groups has attenuated this problem. Nevertheless, they are still acid 
sensitive and, if necessary, must be purified on alumina. The reactions are sufficiently clean such that 
chromatographic purification is not generally necessary, except for the preparation of analytically pure 
samples. The phosphoramidites have been successfully used for the preparation of oligonucleotices 
and though the acid sensitivity of the C8-arylguanines and C8-aryladenines reduces the overall 
coupling efficiency (89% for 10-mers) from that typically observed (98-99%), sufficient quantities of 
modified oligonucleotides can be easily prepared for, for example, NMR studies. 
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